• 1
    Dembo AJ. The ovary. In: MossWT, CoxJD, editors. Radiation oncology: rationale, techniques, results. St. Louis: C.V. Mosby Company, 1989: 581596.
  • 2
    Harris JR, Morrow M, Bonnadonna G. Cancer of the breast. In: De VitaVT, HellmanS, RosenbergSA, editors. Cancer: principles and practice of oncology. 4th edition. Philadelphia: Lippincott Company, 1993: 12641332.
  • 3
    Serber W. Radiation treatment of benign disease. In: PerezCA, BradyLW, editors. Principles and practice of radiation oncology. Philadelphia: Lippincott Company, 1987: 12481257.
  • 4
    Cole MP. Suppression of ovarian function in primary breast cancer. In: ForrestAPM, KunklerPB, editors. Prognostic factors in breast cancer. London: E & S Livingstone, Ltd., 1968: 146156.
  • 5
    Fracchia AA, Farrow JH, DePalo AJ, et al. Castration for primary inoperable or recurrent breast carcinoma. Surg Gynecol Obstet. 1969; 128: 12261234.
  • 6
    Lees AW, Giuuffre C, Burns PE, et al. Oophorectomy versus radiation ablation of ovarian function in patients with metastatic carcinoma of the breast. Surg Gynecol Obstet. 1980; 6: 721724.
  • 7
    Leung SF, Tsao SY, Teo PML, et al. Ovarian ablation failures by radiation: a comparison of two dose schedules. Br J Radiol. 1991; 64: 537538.
  • 8
    Meakin JW, Allt WEC, Beale FA, et al. Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. CMAJ. 1979; 120: 12211229.
  • 9
    Peck WS, McGreer JT, Kretzschmar NR, et al. Castration of the female by irradiation. Radiology 1940; 34: 176186.
  • 10
    Smith D, Dewar JA, Horobin JM, et al. Meakin adjuvant regimen in premenopausal patients with breast cancer. Br J Surg. 1990; 77: 12191220.
  • 11
    Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet. 1996; 348: 11891196.
  • 12
    Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr. 2001; 30: 6771.
  • 13
    Jonat W, Kaufmann M, Sauerbrei W, et al. Gosrelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002; 20: 46284635.